Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
MOTS-c16 residuesMRWQEMGYIFYPRKLREach bubble = one amino acid. Size = residue mass. Color = chemical class.Also known as: MOTS-c, MOTSc
Skeletal muscle MOTS-c levels spike up to 12-fold after a single bout of exercise, then decline steadily with age. The MOTS-c peptide is a 16-amino-acid sequence encoded directly in mitochondrial DNA, one of fewer than ten known signaling molecules produced by the mitochondrial genome. Lee and colleagues showed it reduces obesity and corrects insulin resistance in mice [1]. No completed human therapeutic trial exists yet. Preclinical data is strong, community adoption is growing, and the mechanism, AMPK activation via folate cycle inhibition, overlaps directly with the pathways triggered by physical training.
Skeletal muscle produces 12 times more MOTS-c during exercise than at rest. That single finding about the MOTS-c peptide, confirmed by Reynolds and colleagues in 2021 [2], reframed this molecule from a curiosity to one of the most studied mitochondrial-derived peptides in metabolic research. MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c) is a 16-amino-acid peptide encoded in the 12S rRNA gene of mitochondrial DNA. Its molecular weight is 2174.5 Da, and it belongs to a small family of mitochondrial-derived peptides that also includes humanin. The mechanism centers on folate cycle inhibition in skeletal muscle. Blocking de novo purine biosynthesis triggers AMP-activated protein kinase (AMPK), the same energy-sensing enzyme switched on during physical exercise. Once active, AMPK drives GLUT4 translocation, increases fatty acid oxidation, and shifts cellular metabolism away from storage and toward energy production. The 2015 mouse study by Lee and colleagues [1] remains foundational: MOTS-c reduced diet-induced obesity and restored insulin sensitivity. A 2025 Nature study [3] extended the picture by showing MOTS-c prevents pancreatic beta-cell senescence; circulating levels were reduced in patients with type 2 diabetes. Yin and colleagues reported anti-cancer activity in ovarian cancer models (Advanced Science, 2024). Community users run it at 5 to 10 mg subcutaneous, 2 to 3 times per week, cycling 4 weeks on and 2 to 4 weeks off. Those doses are far below the animal study range of 0.5 to 15 mg/kg/day. Effects are consistent but subtle: improved fasting energy, better exercise tolerance, and modest body composition changes over a cycle. MOTS-c is preclinical, WADA-prohibited, and removed from the FDA Category 2 list on April 15, 2026, with PCAC review beginning July 2026.
MOTS-c works through a chain of metabolic events that starts with folate. The peptide inhibits the folate cycle and its connected de novo purine biosynthesis pathway in skeletal muscle. That metabolic disruption generates ZMP-like intermediates that activate AMPK. Once AMPK is engaged, three downstream effects follow. First, GLUT4 translocates to the cell membrane, pulling glucose into the cell independently of insulin. Second, fatty acid oxidation ramps up. Third, the cell shifts its energy balance from storage toward production. These are the same metabolic shifts triggered by aerobic exercise. Under metabolic stress (glucose restriction or oxidative challenge), MOTS-c does something unexpected. It moves from the cytoplasm into the nucleus through an AMPK-dependent mechanism. Inside the nucleus, it binds to antioxidant response element (ARE) regions of DNA and works with the transcription factor NRF2 to activate stress-response genes. Kim and colleagues mapped this pathway in 2018 [4]. This mitochondria-to-nucleus retrograde signaling allows mitochondria to directly influence nuclear gene expression when the cell is under strain. Endogenous production matters. Reynolds et al. [2] confirmed that MOTS-c levels in skeletal muscle increase up to 12-fold after acute exercise in humans. Those levels decline with aging, tracking closely with age-related metabolic dysfunction.
Well-established AMPK activator in preclinical models with confirmed exercise-mimetic, insulin-sensitizing, and anti-aging effects. Human data is observational only: endogenous MOTS-c levels correlate with metabolic health markers across multiple human studies. No completed therapeutic trials with native MOTS-c. Analog CB4211 completed Phase 1b. Anti-senescence data strong in 2025 Nature study (pancreatic beta cells). Anti-cancer activity emerging (2024 Advanced Science ovarian cancer study).
Lee et al. 2015 (PMID 25738459): seminal study: MOTS-c reduces obesity and improves insulin resistance in mice. Reynolds et al. 2021 (PMID 33473109): MOTS-c is exercise-induced and declines with aging in humans. Nature 2025 (PMID 40855115): MOTS-c prevents pancreatic beta-cell senescence; circulating levels are reduced in T2D patients.
No completed human therapeutic trials with native MOTS-c. All efficacy data from rodent models. No formal SC pharmacokinetics in humans: plasma half-life (~1-2 hours) is inferred from endogenous exercise kinetics, not a dedicated PK study. Conflicting oncology data: some AMPK mechanisms are oncosuppressive while others may promote cancer cell survival depending on tumor type and context. WADA-prohibited: no regulatory oversight of community sourcing.
Positively regarded in metabolic health and longevity biohacker communities. Viewed as a "background" metabolic optimizer: effects are consistent but subtle compared to more dramatic single-compound peptides. Most users run in multi-peptide mitochondrial stacks. High per-cycle cost limits community sample size.
Science and community agree on core mechanism (AMPK activation, exercise mimetic, metabolic improvement) and general outcomes. The dose gap is meaningful: animal studies use 0.5–15 mg/kg while community uses flat 5-10 mg regardless of body weight: for a 70 kg person, that is 0.07-0.14 mg/kg, far below animal study doses. Community effects at these doses are biologically plausible given AMPK sensitivity to small-molecule activators but remain unvalidated in formal human trials.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 5mg | 3x/week |
| Moderate | 10mg | 3x/week |
| Aggressive | 10mg | 5x/week |
Reconstitution math for a 10 mg vial: add 2 mL bacteriostatic water to get 5 mg/mL. A full 100-unit (1.0 mL) insulin syringe then delivers exactly 5 mg. For the 10 mg dose, you'll draw 200 units (2.0 mL), which means splitting between two injection sites at 100 units each. One 10 mg vial equals one dose at the intermediate level. For 5 mg vials: add 1 mL BAC water for the same 5 mg/mL concentration. A full syringe equals the full vial. The thing most beginners miss is timing. MOTS-c fires up AMPK, and that energy signal will keep you awake if you inject past early afternoon. Dose upon waking or 30 to 60 minutes before training. Never after 2 PM. Store lyophilized powder at -20 degrees Celsius. Once reconstituted, refrigerate at 2 to 8 degrees Celsius and use within 28 days. Confirm vendor labels are in mg, not mcg; the community doses MOTS-c in milligrams and a mg/mcg mix-up creates a 1,000-fold error.
MOTS-c cycling is empirically derived. The most plausible rationale is AMPK pathway normalization: continuous overactivation may dysregulate normal energy sensing, suppress anabolic mTORC1 signaling, and potentially trigger excessive autophagy over time. Community reports of diminishing returns after 4-6 weeks of continuous use are consistent with AMPK pathway adaptation. The 8-weeks-on/8-weeks-off variant (Jay Campbell) assumes a longer desensitization window is needed for sustained effect between cycles. Neither pattern has been formally validated.
Or use the universal Peptide Calculator for any peptide.
Expected: Mild energy improvement within 1-2 weeks. Modest fasting glucose reduction and improved exercise tolerance by week 4. Body composition changes minimal at 5 mg dose.
Monitor: Check fasting glucose at baseline and week 4. If on glucose-lowering medications, monitor more frequently: additive insulin-sensitizing effects can lower glucose meaningfully.
Pull 2 mL of bacteriostatic water into a syringe and inject slowly into a 10 mg MOTS-c vial, aiming at the glass wall. Let the powder dissolve without shaking. This gives you a 5 mg/mL concentration.
For a 5 mg dose, draw 100 units (1.0 mL) on a standard U-100 insulin syringe. For a 10 mg dose, draw the full 200 units (2.0 mL) and split between two injection sites.
Pinch a fold of skin at your injection site (abdomen, thigh, or upper arm) and insert at a 45-degree angle.
At the 10 mg dose, inject 100 units at the first site, then move to a second site (e.g., opposite side of the abdomen) for the remaining 100 units.
If you inject three times per week, use at least three distinct sites in rotation to avoid local irritation buildup.
Do not inject after 2 PM.
After reconstitution, store the vial in the refrigerator at 2 to 8 degrees Celsius. Discard after 28 days. Keep unreconstituted vials frozen at -20 degrees Celsius.
Complementary mitochondrial support: MOTS-c drives AMPK/metabolic signaling and nuclear stress-response gene activation, while SS-31 protects mitochondrial cardiolipin and electron transport chain efficiency. Together they address mitochondrial dysfunction through two distinct, non-overlapping mechanisms.
Run concurrently on the same injection schedule
NAD+ replenishment supports the AMPK-SIRT1-PGC1α signaling axis. MOTS-c and NAD+ converge on mitochondrial biogenesis and energy metabolism. A commercial MOTS-c + NAD+ + 5-Amino-1MQ triple blend exists (BioLongevity Labs). Run concurrently.
NNMT inhibitor that raises intracellular NAD+ and activates AMPK signaling via a complementary pathway. The MOTS-c / NAD+ / 5-Amino-1MQ triple stack targets overlapping metabolic pathways and is sold as a pre-formulated commercial blend.
10 mg MOTS-c + 100 mg NAD+ + 10 mg 5-Amino-1MQ per dose (commercial blend format)
Both are mitochondrial-derived peptides (MDPs) encoded in mitochondrial DNA. Humanin is primarily neuroprotective and anti-apoptotic; MOTS-c is metabolic and AMPK-focused. Stacking covers both branches of mitochondrial retrograde signaling.
Both MOTS-c and metformin activate AMPK via overlapping mechanisms. Additive AMPK stimulation significantly increases risk of excessive glucose lowering. Community consensus: avoid unless under physician supervision with active glucose monitoring.
Do not combineMOTS-c promotes insulin-independent GLUT4-mediated glucose uptake. Combined with exogenous insulin or insulin secretagogues, hypoglycemia risk is clinically significant, particularly in fasted or pre-training states.
Do not combineMOTS-c's primary mechanism involves inhibiting the folate cycle. Concurrent antifolate drugs may produce unpredictable additive or antagonistic effects on folate metabolism.
Berberine is a potent AMPK activator. Combining with MOTS-c creates overlapping AMPK stimulation with unpredictable magnitude of glucose-lowering effect.
Pricing updated 2026-04-09
The most serious risk with MOTS-c is hypoglycemia, particularly for anyone taking metformin, insulin, sulfonylureas, or berberine alongside it. MOTS-c activates AMPK and promotes insulin-independent glucose uptake through GLUT4 translocation. Stack that mechanism on top of another AMPK activator or glucose-lowering drug, and fasting glucose can drop fast. Users on these medications should monitor blood glucose actively and discuss timing adjustments with their prescribing physician. No completed human therapeutic trial exists for native MOTS-c. All efficacy and safety data come from animal models and observational human studies. The CB4211 analog completed Phase 1b, but that is a modified compound with its own safety profile. Community experience provides the largest real-world dataset: an estimated 500 to 2,000 active users, with roughly 50 to 150 identifiable threads on r/Peptides. That sample size is modest, and rare adverse events may not yet have surfaced. Injection site reactions are the most commonly reported side effect. Redness, mild swelling, and occasional bruising at the injection site appear frequently in first-week reports. At the 10 mg dose (2 mL injection volume), splitting between two sites at 1 mL each reduces local irritation. Warming the vial to room temperature before injecting also helps. Insomnia and sleep disruption rank second. MOTS-c activates cellular energy metabolism through AMPK, and dosing after 2 PM produces an energy signal that interferes with sleep onset. Community consensus is strict: morning dosing only, upon waking. Sleep issues resolve within 1 to 2 days of switching to morning-only administration for most users. MOTS-c inhibits the folate cycle as its primary mechanism. Anyone taking antifolate medications (methotrexate, trimethoprim) should exercise caution. The interaction is theoretically bidirectional: MOTS-c could increase antifolate toxicity or reduce efficacy depending on context. No clinical data clarifies this interaction. Conflicting oncology data exists. Some AMPK-mediated mechanisms are oncosuppressive; others may promote cancer cell survival depending on tumor type. The 2024 Advanced Science study showed anti-cancer activity in ovarian cancer, but this cannot be generalized across all cancers. Pregnancy and breastfeeding are absolute contraindications. Children and adolescents lack sufficient safety data. Individuals with severe hepatic impairment should use MOTS-c only under clinical supervision, as the peptide is under active research for non-alcoholic fatty liver disease. Stop MOTS-c and consult a physician if fasting glucose drops below 70 mg/dL, if sleep disruption persists despite morning-only dosing, or if injection site reactions do not resolve with site rotation and technique correction.
Verify MOTS-c dosing and safety with a second opinion
MOTS-c is a 16-amino acid peptide with established solid-phase synthesis protocols: purity verification via HPLC/MS is feasible. However, MOTS-c was removed from FDA Category 2 on April 15, 2026, but compounding pharmacy access is not yet available pending PCAC review (July 2026). All current supply comes from unregulated research vendors. Dosing confusion between mg and mcg creates real risk of 1000x errors if vendor labeling is inconsistent.
| Test | When | Target |
|---|---|---|
| Fasting blood glucose | Baseline, mid-cycle (week 2), and end of cycle | 70-100 mg/dL fasted. Stop or reduce dose if consistently below 70 mg/dL or if symptomatic hypoglycemia occurs. |
| HbA1c | Baseline and 3 months post-cycle | <5.7% (normal); <7.0% (T2D management target). |
| Liver function panel (ALT, AST) | Baseline and end of cycle (for cycles >6 weeks) | ALT <40 U/L, AST <40 U/L. Any >2× elevation above baseline warrants stopping. |
| Lipid panel (total cholesterol, LDL, HDL, triglycerides) | Baseline and post-cycle | — |
MOTS-c promotes GLUT4-mediated insulin-independent glucose uptake. Combined with glucose-lowering medications, fasting glucose can drop significantly.
Primary marker for sustained insulin sensitivity improvement. Most relevant for users with pre-diabetes or T2D. Improvement of ≥0.3 percentage points reflects meaningful metabolic effect.
MOTS-c is under active research for non-alcoholic fatty liver disease (NAFLD). Hepatic effects are biologically plausible. Monitoring is prudent for extended cycles or users with known hepatic conditions.
MOTS-c increases fatty acid oxidation. Beneficial shifts in triglycerides and HDL are plausible metabolic markers. Useful for objectively quantifying metabolic response over a cycle.
Minimal noticeable effects. Some users report mildly increased energy levels. AMPK activation begins at the cellular level but outward changes are not yet apparent.
Improved exercise tolerance and endurance may become noticeable. Fasting glucose levels may begin trending downward. Mild increase in daily energy expenditure.
Measurable improvements in insulin sensitivity and fasting glucose. Enhanced fatty acid oxidation may contribute to modest changes in body composition. Exercise recovery time may decrease.
Peak metabolic benefits typically observed. Improved glucose regulation, better exercise capacity, and sustained energy levels throughout the day. Body composition improvements become more apparent.
Benefits gradually diminish over 2-4 weeks after discontinuation. Endogenous MOTS-c production continues but at baseline levels. Most users follow a 4-weeks-on, 2-weeks-off cycle pattern.
Week 1, AMPK activation begins: AMPK fires within hours of each dose through folate cycle inhibition. GLUT4 translocation increases glucose uptake at the cellular level. Some users notice a mild uptick in energy. Most report no dramatic single-compound effect this early. Injection site redness is common in the first few sessions. Do not dose after 2 PM; insomnia reports spike when users ignore this timing rule. Weeks 2 to 3, metabolic shift becomes noticeable: Sustained AMPK activation drives measurable changes in fat oxidation and glucose handling. MOTS-c begins translocating into the nucleus under metabolic stress, activating NRF2 target genes. Community users report improved exercise tolerance, shorter post-exercise fatigue, and more consistent daily energy. Fasting glucose trends lower in metabolically compromised users. Sensitive individuals may still experience mild sleep disruption despite morning dosing. Weeks 4 to 6, peak metabolic benefits: This is the window most users rate highest (3.8 out of 5 overall sentiment). Body composition improvements become visible. Glucose regulation clearly improves. Exercise capacity hits its best point during the cycle and recovery time shortens. Cumulative GLUT4 and fatty acid oxidation effects reach their maximum. Injection site fatigue from repeated rotation is the main complaint at this stage. Post-cycle (off period), washout and normalization: MOTS-c clears rapidly after each dose (plasma half-life approximately 1 to 2 hours). AMPK activity returns to endogenous baseline. Benefits taper over 2 to 4 weeks. Users who maintained training throughout the cycle retain effects longer. Metabolic improvements in glucose handling and body composition appear partially maintained across multiple cycles. Most users follow a 4 weeks on, 2 to 4 weeks off pattern before beginning another cycle.
AMPK is activated within hours of each dose via folate cycle inhibition and ZMP-like signaling. GLUT4 translocation increases glucose uptake. Metabolic gene expression begins shifting within 24-48 hours.
Mild increase in energy noted by some. Slight improvement in fasted morning feeling. Most users report no dramatic single-compound effect. Injection site redness common in first week.
Sustained AMPK activation drives measurable shifts in fat oxidation and glucose utilization. MOTS-c begins nuclear translocation under metabolic stress, activating NRF2-mediated stress-response genes. Mitochondrial biogenesis upregulated.
Improved exercise tolerance and endurance. Fasting glucose trending lower in metabolically compromised users. More consistent daily energy. Post-exercise fatigue noticeably shorter.
Maximum cumulative effect on GLUT4-mediated glucose uptake, fatty acid oxidation, and mitochondrial biogenesis gene expression. Insulin sensitivity improvements are measurable in metabolic studies at this timeframe.
Most users report peak benefits: body composition improvements visible, glucose regulation clearly improved, exercise capacity at its best during cycle. Recovery time shorter. This is the window users rate most positively (3.8/5 overall sentiment).
MOTS-c plasma half-life is approximately 1-2 hours: compound clears rapidly after each dose. AMPK activity returns to endogenous baseline. Downstream transcriptional adaptations (mitochondrial biogenesis, NRF2 target genes) may persist several weeks but normalize gradually.
Benefits taper over 2-4 weeks post-cycle. More sustained in users who maintained training throughout. Most users return to baseline energy by end of off period. Metabolic improvements (glucose, body composition) appear partially maintained across multiple cycles.
Source: Exogenous plasma t½ ~1-2 hours inferred from exercise kinetics; endogenous circulating levels persist 12-15 hours (preclinical estimates)
Loading the interactive decay curve.
MOTS-c has no FDA approval and has not completed human therapeutic trials. Its regulatory status is preclinical. The FDA placed MOTS-c on the Category 2 Bulk Drug Substance list in September 2023. On April 15, 2026, HHS removed MOTS-c from Category 2 along with 11 other peptides. PCAC review begins July 2026. Compounding pharmacy access is not yet available. MOTS-c is currently available only through research-grade peptide suppliers operating outside pharmaceutical regulatory oversight. Quality control varies by vendor; buyers should require Certificates of Analysis with HPLC purity of 98% or higher and mass spectrometry identity confirmation. MOTS-c is prohibited by the World Anti-Doping Agency (WADA). Athletes subject to anti-doping testing risk competition eligibility by using it. This content is for educational and research purposes only. It does not constitute medical advice. Consult a qualified healthcare provider before using any peptide.
Peptide Schedule Research TeamReviewed Apr 202612 Citations
